Are There Limitations in Using Microsatellite Instability as a Biomarker?
While MSI is a valuable biomarker, there are limitations. Not all cancers with MSI-H respond to immunotherapy, and the presence of MSI alone does not provide a complete picture of a tumor's genetic landscape. Additionally, the heterogeneity of tumors means that MSI status can vary within different regions of the same tumor or between primary and metastatic sites.
